TerminatedPhase 4NCT01714648

Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Elisha Hospital
Principal Investigator: Shahar Kol, MD
Elisha Hospital, Haifa, Israel
Intervention: Triptorelin 0.2 mg(drug)
Enrollment: 6 target
Eligibility: 18-42 years · FEMALE
Timeline: 2012 – 2014

Study locations (1)

IVF Unit, Elisha Hospital, Haifa, Israel, Israel

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01714648 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials